From Dark Report — Learn More on How Your Lab Can Benefit from LIS-EMR Integration

 

YOUR PRESENTERS:

Robert D. Atlas, CEO of Atlas Development Corporation

Pat Wolfram, VP Marketing and Client Services, Ignis Systems

 
Robert Atlas
Robert D. Atlas
Pat Wolfram
Pat Wolfram

___________________________________________________________________________

This second tidal wave of EMR adoption by office-based physicians is both a problem and an opportunity for clinical laboratories and pathology groups. It is a problem because many labs continue to be overwhelmed by physician requests to help them implement EMRs and qualify for phase 1 criteria.

It's an opportunity because Meaningful Use phase 2 criteria raises the bar for how physicians must electronically interface with laboratories, particularly for lab-test ordering and lab test results reporting. Labs that "get it right" can win new clients while labs that can't deliver face the risk of losing some of their best-referring physician-clients. 

By now, nine months after the Meaningful Use phase 1 criteria became effective, most labs have some experience developing the required electronic two-way interface between their laboratory information systems (LIS) and the new EMRs installed by physician-clients. 

Now clinical labs and pathology groups are about to face a totally new set of challenges as phase 2 of meaningful use soon kicks in. That makes it essential that you prepare your lab for these next steps. Physicians adopting EMRs will soon ask even more of laboratories in the way of IT integration.

Here's your opportunity to gain a better understanding of the status of phase-1 implementation and find out what you can expect from the fast-approaching phase 2 when you join The Dark Report and DarkDaily.com for their latest audio conference, "Meaningful Use: Phase 1 Lessons Learned and How to Prepare Your Lab for Phase 2 Requirements" on Wednesday, September 21, 2011.

You'll learn from two leading experts why changes to EMR Meaningful Use requirements will affect the way labs must integrate with the EMRs of office-based physicians. Listen as our experts reveal what they've learned about integrating labs to the new EMRs in phase 1. 

Not only will you get valuable updates on the latest Meaningful Use requirements during this audio conference, but you'll also acquire tactics for dealing with them successfully.

First to speak will be Pat Wolfram, of Ignis Systems who's an expert in both EMR systems and how these systems handle lab test data—including placing electronic lab-test orders and accepting structured lab test results into patient records. 

Wolfram will give you a better understanding of the specific EMR products being adopted by physicians in your area. You'll learn about their strengths and weaknesses, particularly when it comes to supporting electronic ordering of lab tests and reporting results. You'll also get a valuable preview of the newest generation of EMR products now coming to market.

Most important, you'll get a roadmap for crafting a strategy that will help your laboratory implement an interface between the LIS and the EMR to deliver clean, complete electronic test orders to your lab, which will help your valued physician-clients meet both phase 1 and phase 2 critera.

Our second speaker, Robert D. Atlas of Atlas Development Corporation, has considerable experience in web-browser-based services that support lab test orders/reporting by physicians. Atlas will help you understand the current state of the marketplace-and the mix of informatics capabilities your lab should be ready to deliver to high-referring office-based physicians.

Find out why to expect the unexpected—and what specific action steps your lab should take to gain competitive advantage and use your LIS-to-EMR strengths to win profitable new business. 

Whether you're a lab administrator, pathologist, or industry consultant, you need to stay on top of these significant changes involving Meaningful Use and LIS-to-EMR interfaces. Register today to guarantee your place at this essential learning session. 

Don't lose your physicians to competing labs! Make sure you can deliver an effective LIS-to-EMR interface right now by registering for this very timely audio conference today. Don't forget that your entire lab and IT team can learn and participate when you register.

THE DARK REPORT AUDIO CONFERENCE AT A GLANCE

DATE: Wednesday, September 21, 2011

TIME:
 1 p.m. EDT; 12 p.m. CDT; 11 a.m. MDT; 10 a.m. PDT

PLACE:
 Your telephone or speakerphone

COST:
 $195 per dial-in site (unlimited attendance per site) through 9/9/11, $245 thereafter

TO REGISTER NOW:
 Click here or call 1-800-560-6363 toll-free

For one low price—just $195 (through 9/9/11; $245 thereafter)—you and your entire team can take part in this fast-paced, insightful audio conference. Best of all, you'll be able to connect personally with either of the panelists when we open up the phone lines for live Q&A.

Here's just some of what you’ll learn during this in-depth 90-minute conference:

  • The changes expected from Meaningful Use phase 2 criteria and why your lab needs to be ready.

  • Lessons from Meaningful Use phase 1—what works best for labs when helping physicians adopt EMRs.

  • Why even certified EMRs fall short of doing a good job handling structured lab tests results. 

  • Fast, cheap, and effective methods your lab can use to connect to physician EMRs and deliver extraordinary customer service. 

  • How to recognize when your lab's best clients are at risk during EMR implementation-and how to keep them happy.

  • LOINC's potential to help your lab deliver doctor-pleasing lab test order/results reporting capabilities.

  • How to effectively integrate with current EMR systems.

  • EMR Meaningful Use requirements and what they mean for your lab in phase 2.

  • Which government programs can help with the public health reporting requirements.

  • Why information technology is your lab's trump card to become a key player in the emerging connected-care paradigm.

  • Benefits of clean-order capture: the secrets of synchronizing orders from EMRs with results from the LIS so your lab captures a clean order, distributes the right result, files a clean claim, and gets paid on first submission.

  • How to unleash the power of a robust rules engine and embedded web services order-entry platform in the physician's EMR to enhance the clinician's workflow while improving lab test utilization. 

  • How technological solutions can enhance lab capacity and improve functional capability without adding to lab IT staff.

    …plus much more!

How to Register:
1. Online
2. Call toll free: 800-560-6363.

Your audio conference registration includes:

  • A site license to attend the conference (invite as many people as you can fit around your speakerphone at no extra charge)
  • Downloadable PowerPoint presentations from our speakers
  • A full transcript emailed to you soon after the conference
  • The opportunity to connect directly with our speaker during the audience Q&A session

    Register Now! Or for more information, call us toll-free at 800-560-6363. 
Distinguished Presenters:

Robert AtlasRobert D. Atlas is CEO of Atlas Development Corporation. He has been involved in Lab IT for more than two decades, as a manager of information systems, a software designer/developer and an IT products vendor. He is well known in the Caché/M world, having spent six years at InterSystems Corporation, where he was instrumental in helping to evolve its technology. Mr. Atlas served on the ANSI SQL Development Committee and also served as Chairman of the InterSystems Database End-users Association for several years. In 1989, he co-founded Atlas Development, which has developed a number of high-performance, mission-critical applications for healthcare industry leaders. Mr. Atlas is a graduate of the Massachusetts Institute of Technology.

 


Pat WolframPat Wolfram is Vice President Marketing and Customer Services at Ignis Systems Corporation. He has more than 15 years experience integrating electronic medical records (EMR) with lab services, radiology departments, hospital CDRs, and HIE repositories. His team works with physicians and their staffs implementing orders and results into the each practice's EMR workflow. Ignis Systems was commissioned by CCHIT (Certification Commission for Health Information Technology) to create test suites to validate Lab-to-EMR integration. Prior to Ignis, Mr. Wolfram was the vice president of EMR integration at MedicaLogic and the global product manager for EMR integration at GE Healthcare. He is a past chairman of the HL7 marketing committee and a recipient of the Chairman's Achievement Award at Mentor Graphics.

 


Yes, i want to register Now!

 

ACCENT® Continuing Education Credit
The American Association of Clinical Chemistry (AACC) designates this program for a maximum of 1.5 ACCENT® credit hours towards the AACC Clinical Chemist’s Recognition Award. AACC is an approved provider of continuing education for clinical laboratory scientists in the states of California, Florida, Louisiana, Montana, Nevada, North Dakota, Rhode Island, and West Virginia.


 

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Flagship Biosciences launches integrated DNA and protein tumor heterogeneity testing

FLAGSTAFF, Ariz. — September 7, 2011 — Flagship Biosciences, a leading provider of FFPE and frozen tissue analysis for pharmaceutical and medical device development, announced today the launch of new heterogeneity testing services. These patent-pending techniques have been developed by in-house scientists at Flagship for better assessment of the variability of a DNA mutation or a protein expressed in tissue. Rather than assuming that a tissue sample is homogenous, the approach embraces the concept that heterogeneity can be critical biological information, and its evaluation a potential prognostic for therapy.

“Heterogeneity is a reflection of the plasticity of tumor cells” said Dr. Joseph Krueger, Director of Biology at Flagship Biosciences “This plasticity is regulated by both gene mutations and epigenetic gene product regulation.  These processes can create sub-populations of cells within a tumor which are inherently resistant or acquire resistance to a targeted therapy.  The current techniques for assessing a diagnostic marker to select patients for targeted therapies fail to account for the heterogeneity commonly seen in most types of cancer.”

The DNA mutation analysis service is a combination approach of both real-time PCR and repeated Sanger sequencing, using a proprietary method of normalization when analyzing ratios between wildtype and novel and known point mutations. The method identifies mutations in a sample as well as measuring the percentage of tissue with each mutation.

The IHC heterogeneity analysis relies on a proprietary tumor heterogeneity score called HetMap that reports both cell-level heterogeneity and tumor-level heterogeneity in the same tissue block utilized to determine the DNA mutation analysis. With IHC multiplexing, the HetMap score can evaluate additional markers and the interactions of markers as necessary. 

“The recent clearances in companion diagnostics for specific mutations in melanoma and lung cancer demonstrate the importance of evaluating heterogeneity in tissue.  Despite having a driving mutation in these tumors, 40-50% of selected patients will not show a response to drugs which target these mutations.  This could be because of variability in tumor cells having that mutation, or other independent factors which cause insensitivity to the drug in sub-populations of cells” added Joseph Krueger.  “Determining mutation penetration and the variance in the expression of specific proteins can point to the underlying cause for refractory disease. Incorporating assessments of tumor heterogeneity as part of a diagnostic will facilitate better prediction of a patient’s potential for response, and will provide rationale and selection for therapy regimens that will increase the response rates of these refractory patients.

The DNA heterogeneity complements the IHC heterogeneity measurement.  The penetrance of a particular mutation can be correlated to specific factors assessed by IHC.  While immunohistochemisty is a semiquantitative technique, it has the exquisite advantage of cell-level protein expression analysis, with cellular details and contextual information about the expression of a protein in nests of cells.

The image analysis and pathology techniques behind HetMap will be presented at the Pathology Visions 2011 conference, the premier conference on Digital Pathology. Specific applications will be presented at the CTRC-AACR San Antonio Breast Cancer Symposium meeting this year.  Publications describing these novel approaches are being submitted for publication this year.

Flagship Biosciences is a pathology CRO, that specializes in tissue-based companion diagnostics, and histopathology assessment of efficacy and toxicity using brightfield and fluorescent whole slide imaging. 

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Broaden your professional background by serving as the Editor-in-Chief for LabMedicine

ASCP seeks an Editor-in-Chief for LabMedicine, the Society's journal for laboratory professionals.

This paid volunteer role has the responsibility for the overall strategic direction of LabMedicine, one of ASCP's most visible and important member benefits.

The Editor-in-Chief will also work with our editorial board and internal ASCP staff to implement a comprehensive new strategic direction for the journal.

To be considered, candidates must have:

  • Experience working with scientific journals; as an author, editor, editorial board member, or reviewer
  • A doctoral degree or medical degree, in some facet of laboratory medicine. Masters level candidates will also be considered.
  • Broad medical knowledge, high ethical standards, strategic planning skills, and a commitment to improving patient care.

A monthly stipend will be offered. For details and to apply, click here

View Job Posting

If you experience any problems linking to the URL or viewing the job posting, please send an email to recruiting@chicago.ascp.org.

 

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

CBLPath Exhibiting at CAP ’11 Booth #217 in September

Best Practice™ Workshop Set for Monday, Sept. 12, at 6:15 p.m.

RYE BROOK, N.Y., Aug. 16, 2011 — CBLPath will showcase its Best Practice™ Partnership Program at the upcoming College of Pathologists (CAP) annual meeting, Booth #217. The company will provide attendees with valuable information about how they can leverage the convergence of anatomic, molecular and digital pathology to stay independent — Keeping Medicine Local™. CAP ’11 – THE Pathologists’ Meeting™ takes place September 11–14 in Grapevine (Dallas/Ft. Worth) Texas.

CAP ’11 attendees can learn more about CBLPath’s innovative Best Practice program — offering local pathology practices a full range of business and technology solutions — and get the most from the meeting with:

  • Demos of LabIS®, CBLPath’s proven pathology management system
  • The chance to speak with Program Partners
  • An informative Best Practice workshop on Monday, Sept. 12, at 6:15 p.m.
  • A Relaxation Station that offers chair massages to meeting attendees
  • Local representatives from across the U.S. to talk with prospective partners

For more about the CAP ’11 meeting, visit http://www.cap.org/cap11.

About CBLPath
CBLPath is a national specialty lab with a unique leadership position in the convergence of anatomic, molecular and digital pathology. Beginning from a clinical perspective, we harness molecular testing and digital pathology on an anatomic pathology foundation. CBLPath is committed to helping our clients deliver better medicine, faster. At our core are pathologists; excited about technology and innovation and its promise of helping patients. Through the Best PracticeTM Partnership Program we help our pathologist-clients effectively compete against centralized reference laboratories, grow their Practice and remain independent — Keeping Medicine Local™. We provide our subspecialty physician clients comprehensive diagnostics and timely, accurate reports enabling the best patient care. For more about the company, please visit http://www.CBLPath.com.

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Anatomy in Korea with Dr. Oh














A few days ago, I met with the very lovely and generous anatomist Dr. Chang-Seok Oh, referred to me by my friend Ross MacFarlane. I had been interested in viewing medical or old natural history collections here in Seoul, and Dr. Oh had kindly offered to take me to see an anatomical collection of a Catholic university hospital where he had a contact. The collection had a number of interesting pieces, the most outstanding being a 17th Century mummy unearthed at an archeological excavation; there were also a number of forensic reconstructions. Images of the collection can be seen above.

Dr. Oh then took me back to his office, where we gushed about our shared interest in post-Vesalius/pre-Gray's Anatomy anatomical history, and where he shared with me his beautiful original copy of the 18th century Ontleedkundige Tafelen. This book, Dr. Oh explained to me, is of the greatest importance to Asian medicine, as it was the first Western medical book translated for Eastern consumption, published in Japan (with some additions from other texts) as Kaitai Shinsho in 1774. The book then made the rounds in Asia, changing the face of Eastern medicine forever. We did a side by side comparison of the original book and a facsimile of the 18th century Japanese Kaitai Shinsho; you can see those side by side comparisons above. I really liked the visual translation that occurs as the images move from the West to the East.

Click on images to see much larger, more detailed versions. Its worth it! And thanks to Ross MacFarlane and Deborah Leem for making this happen!

Source:
http://morbidanatomy.blogspot.com/feeds/posts/default?alt=rss

Prints and the Pursuit of Knowledge in Early Modern Europe, Exhibition, Through December 10th




I have just been alerted to a pretty great looking exhibition on through December 10th at the Arthur M. Sackler Museum at Harvard. Entitled "Prints and the Pursuit of Knowledge in Early Modern Europe," the exhibition features not only prints but also flap anatomies (!!!), books, maps, and scientific instruments, all intended to explore "the role of celebrated artists in the scientific inquiries of the 16th century."

Full information follows, from the exhibition website:

Prints and the Pursuit of Knowledge in Early Modern Europe
Sep 6 2011 — Dec 10 2011
Arthur M. Sackler Museum

Prints and the Pursuit of Knowledge examines how celebrated Northern Renaissance artists contributed to the scientific investigations of the 16th century. The exhibition and its accompanying catalogue challenge the perception of artists as illustrators in the service of scientists. Artists’ printed images served as both instruments for research and agents in the dissemination of knowledge. The exhibition, displaying prints, books, maps, and such instruments as sundials, globes, astrolabes, and armillary spheres, looks at relationships between their producers and their production, as well as among the objects themselves. The story of 16th-century technology is enhanced by technology of the 21st, with interactive computers in the galleries, an interactive module on the website, and an iPhone/iPad application in iTunes (check back here soon for an update on availability).

Curated by Susan Dackerman, Carl A. Weyerhaeuser Curator of Prints, Division of European and American Art, Harvard Art Museums. Organized in collaboration with the Mary and Leigh Block Museum of Art, Northwestern University, Evanston, IL.

Opening Panel Discussion and Reception: September 6, 2011, 5–8pm.
Symposium: December 2, 2011, 5–8pm (evening program), and December 3, 2011, 8:30am–6:30pm (day program).

For more special programming related to the exhibition, such as tours, talks, concerts, and Family Days, see the Prints and the Pursuit of Knowledge section of our calendar.

Admission note: During Prints and the Pursuit of Knowledge, admission to the Sackler Museum galleries will be free on Tuesday, Wednesday, and Thursday, 3–5pm.

Travel dates:
– September 6–December 10, 2011
Harvard Art Museums
Arthur M. Sackler Museum, Cambridge, MA
– January 17–April 8, 2012
Mary and Leigh Block Museum of Art
Northwestern University, Evanston, IL

The exhibition and its accompanying catalogue are made possible by funding from the National Endowment for the Humanities, Mrs. Arthur K. Solomon, Lionel and Vivian Spiro, Walter and Virgilia Klein, Julian and Hope Edison, Novartis on behalf of Dr. Steven E. Hyman, the Samuel H. Kress Foundation, Barbara and the late Robert Wheaton, the Goldman Sachs Foundation, and an anonymous donor. Additional support is provided by the Harvard Art Museums’ endowment funds: the Alexander S., Robert L., and Bruce A. Beal Exhibition Fund; Anthony and Celeste Meier Exhibitions Fund; Charlotte F. and Irving W. Rabb Exhibition Fund; and Melvin R. Seiden and Janine Luke Fund for Publications and Exhibitions.

You can find out more by clicking here; you can find out about--an order a copy of!--the catalog by clicking here.

Thanks to Daniel Margocsy, who helped put it together, for passing this along!

Images all drawn the exhibition page; full info including captions can be found by clicking here.

Source:
http://morbidanatomy.blogspot.com/feeds/posts/default?alt=rss

Bill Nye: 100 Greatest Discoveries : Biology (Discovery Channel) 1/3

Please Subscribe To The WhyEvolutionIsTrue Youtube Channel. http://www.youtube.com 100 Greatest Discoveries Episode List: tinyurl.com Discovery Channel Documentary List: tinyurl.com Broadcast (2007) Where would we be today if it weren't for the scientists of the past? From the miniature world of genetics to the vast expanse of space, review the greatest discoveries of all time across eight different scientific categories in this multi-part series.

See more here:

Bill Nye: 100 Greatest Discoveries : Biology (Discovery Channel) 1/3

Stem Cell Therapy Injections

Stem Cell therapy, is one form of Comprehensive Prolotherapy available for arthritis treatment, and other chronic pain conditions at Caring Medical and Rehabilitation Services. Our same-day procedure utilizes a person's own mesenchymal stem cells from bone marrow to treat degenerated joints. In this video, the stem cell therapy treatment is demonstrated on an athlete with severe osteoarthritis of the knee, by Ross Hauser, MD.

Read the original:

Stem Cell Therapy Injections

Ancient Alien ( demons ) Nephilim Giants, Mutants Genetic Engineering and Hybrids.avi

Daniel 2:43.........And whereas thou sawest iron mixed with miry clay,THEY SHALL MINGLE THEMSELVES WITH THE SEED OF MEN: but they shall not cleave one to another, even as iron is not mixed with clay. They will mix Demons with humans, creating them to be used for the lie, pretending them to be from another planet, the so called aliens ( demons ), will mislead men this way, it is satans final attempt to mislead men

The rest is here:

Ancient Alien ( demons ) Nephilim Giants, Mutants Genetic Engineering and Hybrids.avi